Literature DB >> 17043527

Fracture complicating the bone marrow edema syndrome.

Sherry A Guardiano1, James Katz, Arnold M Schwartz, Kathleen Brindle, Rudolfo Curiel.   

Abstract

Bone marrow edema syndrome (BMES), also known as transient regional osteoporosis, is a rare and poorly understood disease process. We present a case of an elderly patient with the BMES who had a relapsing and remitting course complicated by a hip fracture which presented the unique and a previously unreported opportunity to examine the bony architecture pathologically. The patient responded well to calcitonin and bisphosphonate therapy after surgical repair of his fracture.This case highlights an underappreciated potential complication of BMES. Though not previously reported in the literature, BMES may be associated with active osteoporotic changes, with an infrequent risk of fracture that may be amenable to potential therapeutic interventions. Pathologically, BMES may represent a spectrum of disease consisting of an osteoclast-rich phase (transient regional osteoporosis phase) predisposing to fracture in addition to the more indolent osteoclast-poor phase with bone marrow edema more commonly associated with the disease. We hypothesize that it is the osteoclastic-rich phase which may benefit from early introduction of weight bearing activities, calcitonin, bisphosphonates, or parathyroid hormone. For example, bisphosphonates reduce bone resorption directly. Indirectly, bisphosphonates may also increase osteoblast differentiation and number and thus improve bone quality, an added benefit in the treatment of bone involved in the BMES, whether in the osteoclast-rich or osteoclast-poor phase.Further study should evaluate this osteoclastic-rich phase, which may be a transient pathologic phenomenon and which has not been described previously. Transient regional osteoporosis, therefore, may represent one point in the spectrum of the BMES. Hence, we would argue that BMES is a more accurate name for the full spectrum of this disease entity.

Entities:  

Year:  2004        PMID: 17043527     DOI: 10.1097/01.rhu.0000141509.18395.3c

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  8 in total

Review 1.  Bone marrow lesions: a universal bone response to injury?

Authors:  Erik Fink Eriksen; Johan Diederich Ringe
Journal:  Rheumatol Int       Date:  2011-09-08       Impact factor: 2.631

Review 2.  Transient osteoporosis of the hip: review of the literature.

Authors:  K Asadipooya; L Graves; L W Greene
Journal:  Osteoporos Int       Date:  2017-03-17       Impact factor: 4.507

3.  Transient osteoporosis of the hip: successful treatment with teriparatide.

Authors:  Gianluigi Fabbriciani; Matteo Pirro; Maria Rosaria Manfredelli; Massimo Bianchi; Silvio Sivolella; Anna Maria Scarponi; Elmo Mannarino
Journal:  Rheumatol Int       Date:  2010-03-18       Impact factor: 2.631

4.  Effectiveness of extracorporeal shock wave therapy in bone marrow edema syndrome of the hip.

Authors:  Cristina d'Agostino; Pietro Romeo; Vito Lavanga; Salvatore Pisani; Valerio Sansone
Journal:  Rheumatol Int       Date:  2014-11       Impact factor: 2.631

Review 5.  Treatment of bone marrow lesions (bone marrow edema).

Authors:  Erik F Eriksen
Journal:  Bonekey Rep       Date:  2015-11-25

6.  Multimodal conservative treatment of migrating bone marrow edema associated with early osteonecrosis of the hip.

Authors:  Cristiano Sconza; Francesco Coletta; Nicola Magarelli; Maria Cristina D'Agostino; Colin Gerard Egan; Berardo Di Matteo; Stefano Respizzi; Gherardo Mazziotti
Journal:  SAGE Open Med Case Rep       Date:  2022-02-15

Review 7.  Transient Hip Osteoporosis: Etiopathogenetic, Clinical, and Imaging Approach.

Authors:  Nathalie Maisi; Dimitrios Patoulias; Christos Tsagkaris; Michail Tsagatakis; Dimitrios Goules
Journal:  Mediterr J Rheumatol       Date:  2022-06-30

8.  Transient osteoporosis of the hip and subclinical hypothyroidism: an unusual dangerous duet? Case report and pathogenetic hypothesis.

Authors:  Marco Paoletta; Antimo Moretti; Sara Liguori; Matteo Bertone; Giuseppe Toro; Giovanni Iolascon
Journal:  BMC Musculoskelet Disord       Date:  2020-08-13       Impact factor: 2.362

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.